Saba Beigh
Jamia Hamdard, India
Title: Ellagic acid ameliorates bleomycin induced lung toxicity in Wistar rats
Biography
Biography: Saba Beigh
Abstract
Bleomycin (BLM), widely used in cancer chemotherapy and lung toxicity, is a major deterrent in its clinical use. Ellagic acid (EA) is a good protective agent because it has rich antioxidant content. We wanted to study the prophylactic effect of EA on the toxicity profile of BLM. Wistar rats were exposed to BLM (10 mg/kg b.w., intratracheally) and EA (30mg/kg b.w., orally) for 14 days of treatment schedule. Lung fibrosis was measured by checking the level of hydroxyproline which was supported by massive trichome analysis to check the level of fibrosis. Antioxidant profile and inflammatory markers were also measured in lung tissue as well as in bronchoalveolar lavage fluid (BALF). Study was supported by immunohistochemical examination of some pro-inflammatory proteins and apoptotic protein like NF-kB, iNOS, COX-2 and caspase-3 expression. In exposed animals, there was a significant increase in the level of hydroxyproline level. Various antioxidant enzyme activities such as glutathione peroxidase, glutathione reductase and superoxide dismutase were declined when exposed to BLM which was significantly restored by EA pretreatment. EA treatment modulates enhanced myloperoxidase, lactate dehydrogenase and alkaline phosphatase activity in lung tissue as well as in BALF. Treatment of EA caused significant decrease in lipid peroxidation level and increase in reduced-glutathione content. Massive trichome staining analysis strongly support the onset of pulmonary fibrosis and biochemical alterations showing changes such as inflammation and fibrosis in BLM treated lungs which was attenuated by EA. EA acid proved as a powerful protective agent against BLM induced acute lung toxicity.